-
公开(公告)号：US20220259320A1
公开(公告)日：2022-08-18
申请号：US17682922
申请日：2022-02-28
发明人： Jeffry D. Watkins , Cindy T. Dickerson , Rafael Rojas , Matthew Reissman , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11999789B2
公开(公告)日：2024-06-04
申请号：US17682922
申请日：2022-02-28
发明人： Jeffry D. Watkins , Cindy T. Dickerson , Rafael Rojas , Matthew Reissman , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
IPC分类号： C07K16/24 , A61P1/04 , C07K16/28 , A61K39/395 , C07K14/52 , C07K14/525
CPC分类号： C07K16/2875 , A61P1/04 , C07K16/241 , C07K2317/21 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/76
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US20230192835A1
公开(公告)日：2023-06-22
申请号：US17931049
申请日：2022-09-09
发明人： Jeffry D. Watkins , Cindy T. Dickerson , J. Monty Watkins , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
CPC分类号： C07K16/24 , A61P1/04 , C07K16/241 , C07K16/28 , A61P1/00 , A61K9/0019 , C07K16/2875 , C12N15/09 , C12N15/63 , C12N5/10 , A61K39/3955
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11136386B2
公开(公告)日：2021-10-05
申请号：US17118441
申请日：2020-12-10
摘要： Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
-
公开(公告)号：US20240327532A1
公开(公告)日：2024-10-03
申请号：US18645261
申请日：2024-04-24
发明人： Jeffry D. Watkins , Cindy T. Dickerson , Rafael Rojas , Matthew Reissman , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
CPC分类号： C07K16/2875 , A61P1/04 , C07K16/241 , C07K2317/21 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/76
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11440954B2
公开(公告)日：2022-09-13
申请号：US16863971
申请日：2020-04-30
发明人： Jeffry D. Watkins , Cindy T. Dickerson , J. Monty Watkins , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
IPC分类号： C07K16/24 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/63 , A61P1/04 , A61P1/00 , A61K9/00 , C07K14/525 , C07K14/715 , A61K39/395 , A61K39/00
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11292848B2
公开(公告)日：2022-04-05
申请号：US17110004
申请日：2020-12-02
发明人： Jeffry D. Watkins , Cindy T. Dickerson , Rafael Rojas , Matthew Reissman , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
IPC分类号： C07K16/24 , C07K16/28 , A61P1/04 , C07K14/52 , C07K14/525 , A61K39/395
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11186872B2
公开(公告)日：2021-11-30
申请号：US16084858
申请日：2017-03-17
发明人： Rebecca Gonsky , Stephan R. Targan , Richard L. Deem , Philip Fleshner , Dermot P. McGovern , Janine Bilsborough
IPC分类号： C12Q1/6883 , C12Q1/6806 , C12Q1/686 , C12Q1/6834
摘要： Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.
-
公开(公告)号：US20190247498A1
公开(公告)日：2019-08-15
申请号：US16384521
申请日：2019-04-15
CPC分类号： A61K39/39533 , A61K39/3955 , A61K48/005 , A61K2039/505 , A61P1/02 , A61P29/00 , A61P37/00 , C07K16/241 , C07K16/2809 , C07K16/2875 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要： Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
-
10.发明申请MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS 审中-公开通过TL1A功能和相关信号通路的抑制来减轻和反转纤维化和炎症反应公开(公告)号：US20160060335A1
公开(公告)日：2016-03-03
申请号：US14779893
申请日：2014-03-27
发明人： David Q. Shih , Stephan R. Targan , Dalin Li , Janine Bilsborough
IPC分类号： C07K16/24 , G01N33/68 , C12N15/113 , C12Q1/68 , A61K39/395 , A61K45/06
CPC分类号： C07K16/24 , A61K39/3955 , A61K45/06 , C07K16/2875 , C07K2317/76 , C12N15/1138 , C12N2320/30 , C12Q1/6883 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N33/6869 , G01N2333/7155 , G01N2800/065 , G01N2800/10
摘要： The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
摘要翻译： 本发明涉及治疗纤维化和炎症性肠病的方法。 在一个实施方案中，本发明通过向个体施用治疗有效剂量的TL1A抑制剂和/或DR3抑制剂来治疗肠道炎症。 在另一个实施方案中，本发明提供通过抑制TL1A-DR3信号转导功能来逆转个体组织纤维化的方法。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.036 秒)
